{"id":"W4404502581","doi":"10.1080/22221751.2024.2432353","title":"Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial","year":2024,"lang":"en","type":"article","venue":"Emerging Microbes & Infections","topic":"Viral Infections and Outbreaks Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal","funders":"European and Developing Countries Clinical Trials Partnership; Janssen Alzheimer Immunotherapy Research And Development; Janssen Biotech; Innovative Medicines Initiative; Université de Bordeaux; Ministère de l'Enseignement Supérieur et de la Recherche; Center for Biomedical Informatics and Information Technology, National Cancer Institute; European Commission; Frederick National Laboratory for Cancer Research; Institut National de la Santé et de la Recherche Médicale; Bavarian Nordic; Merck Sharp and Dohme; Centre National de la Recherche Scientifique; National Cancer Institute; European Federation of Pharmaceutical Industries and Associations; National Institutes of Health; National Institute of Allergy and Infectious Diseases; Horizon 2020; London School of Hygiene and Tropical Medicine","keywords":"Ebola vaccine; Medicine; Virology; Ebola virus; Antibody; Antibody response; Disease; Immunology; Ebolavirus; Virus; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004331531,0.0002784885,0.0007103137,0.0005480318,0.0003325402,0.0001160329,0.00009499468,0.00008914847,0.000469379],"category_scores_gemma":[0.001298543,0.0001934843,0.0004180001,0.0007333618,0.0001702539,0.0002409115,0.000134066,0.0004325972,0.0000125166],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000104995,"about_ca_system_score_gemma":0.0004419494,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00517147,"about_ca_topic_score_gemma":0.0003842429,"domain_scores_codex":[0.9961642,0.00151108,0.0008634509,0.0004879106,0.0006841323,0.0002892354],"domain_scores_gemma":[0.9971956,0.001372607,0.0001620703,0.0004764247,0.0006656203,0.0001276491],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6112972,0.0056167,0.02202898,0.0007967438,0.006508079,0.0000723969,0.01707431,0.01187091,0.3024447,0.0002096831,0.0007930569,0.02128721],"study_design_scores_gemma":[0.6130276,0.002560347,0.01639524,0.003317988,0.01770858,0.00006582307,0.002526945,0.3261702,0.01338051,0.0016659,0.002348173,0.000832606],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9803702,0.008416246,0.006207884,0.0003200466,0.0005953581,0.00366223,0.0001406658,0.0001066869,0.0001807144],"genre_scores_gemma":[0.997808,0.0007650206,0.0001421591,0.00002823849,0.0004154347,0.0005274241,0.00004627709,0.00005039043,0.0002170771],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3142993,"threshold_uncertainty_score":0.7890059,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04169267854866104,"score_gpt":0.3867564232231482,"score_spread":0.3450637446744871,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}